Global Intraocular Lens Market valued at $3.9 billion in 2021, is set to witness a growth of 5-6% in the next 5 years but is likely to be impacted by Recession in 2022-23
November 23, 2022 09:00 ET
|
Medi-Tech Insights
BRUSSELS, Belgium, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Intraocular lenses (IOLs) are permanent, artificial lenses that are mostly made of silicone, acrylic, or other plastic compositions and can...
Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
November 22, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
November 22, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 22, 2022 08:00 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
November 22, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis
November 22, 2022 06:00 ET
|
Oculis
Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis ...
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
November 22, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
With 3.7% CAGR, Cataract Devices Sales to Reach a Market Size of US$ 19.49 Billion By 2032
November 16, 2022 02:30 ET
|
FACT.MR
Paris, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Fact.MR has provided detailed information about the price points of key manufacturers of cataract devices positioned across regions, sales growth, production...
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
November 14, 2022 08:00 ET
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the company...
RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
November 10, 2022 16:05 ET
|
RVL Pharmaceuticals plc
-- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics...